Lincluden Management Ltd. Purchases 833 Shares of GSK plc (NYSE:GSK)

Lincluden Management Ltd. boosted its position in shares of GSK plc (NYSE:GSK) by 1.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 66,001 shares of the pharmaceutical company’s stock after purchasing an additional 833 shares during the quarter. Lincluden Management Ltd.’s holdings in GSK were worth $2,698,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Eastern Bank acquired a new position in shares of GSK in the 3rd quarter valued at approximately $26,000. Concord Wealth Partners lifted its stake in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in GSK in the 2nd quarter valued at approximately $37,000. Fortitude Family Office LLC bought a new stake in GSK in the 3rd quarter valued at approximately $42,000. Finally, PrairieView Partners LLC bought a new stake in GSK in the 2nd quarter valued at approximately $47,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at GSK

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 10.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GSK has been the topic of several research reports. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating, one has assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.00.

GSK Stock Performance

GSK opened at $36.74 on Friday. The firm has a market cap of $76.15 billion, a P/E ratio of 23.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.65. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The business’s fifty day moving average is $40.78 and its 200-day moving average is $41.05.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. The business had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. GSK had a return on equity of 51.23% and a net margin of 7.97%. Sell-side analysts expect that GSK plc will post 4.08 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a $0.3928 dividend. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.28%. GSK’s dividend payout ratio (DPR) is 100.00%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.